Evidence map›Paper›PMID 41156245›Full record

ArticleJournal of clinical medicine2025

Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data.

Buket Şahin Çelik, Aslı Geçgel, Oğuzcan Özkan, Nargiz Majidova, Buket Erkan Özmarasalı, Gözde Ağdaş, İsmail Bayrakçı, Türkkan Evrensel, Erhan Gökmen

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Buket Şahin ÇelikEge University Faculty of Medicine Hospital, 35100 İzmir, Türkiye.ORCID 0009-0006-0816-5397
Aslı GeçgelEge University Faculty of Medicine Hospital, 35100 İzmir, Türkiye.ORCID 0000-0001-6942-9858
Oğuzcan ÖzkanEge University Faculty of Medicine Hospital, 35100 İzmir, Türkiye.ORCID 0000-0002-4075-7775
Nargiz MajidovaMarmara University Faculty of Medicine Hospital, 34854 İstanbul, Türkiye.ORCID 0000-0002-2575-5819
Buket Erkan ÖzmarasalıUludağ University Faculty of Medicine Hospital, 16059 Bursa, Türkiye.ORCID 0000-0003-2843-2748
Gözde AğdaşEskişehir Osmangazi University Faculty of Medicine Hospital, 26040 Eskişehir, Türkiye.ORCID 0000-0001-9771-6483
İsmail BayrakçıTrakya University Faculty of Medicine Hospital, 22030 Edirne, Türkiye.ORCID 0000-0002-5785-8273
Türkkan EvrenselUludağ University Faculty of Medicine Hospital, 16059 Bursa, Türkiye.ORCID 0000-0002-9732-5340
Erhan GökmenEge University Faculty of Medicine Hospital, 35100 İzmir, Türkiye.ORCID 0000-0003-4596-2986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CDK4/6 inhibitorchemotherapyendocrine therapyeverolimusmetastatic breast cancersurvival outcomes

Identifiers

PMID41156245
PMCPMC12565699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.